Retatrutide: The Complete Guide (Including Common Misspellings)

Primary Keywords: retrutide, retatutride, reditrutide, retattrutide, retartrutide, retatrudtide, retatruride

If you searched for retrutide, retatutride, reditrutide, or something close — you're in the right place. You're looking for retatrutide, Eli Lilly's next-generation weight loss and metabolic drug that's been making headlines. Easy word to misspell. Hard drug to ignore.

Quick Facts: What You Need to Know

⚡ Key Takeaways

• Full name: Retatrutide (also written as LY3437943)
• Developer: Eli Lilly and Company
• Mechanism: Triple receptor agonist — targets GLP-1, GIP, and glucagon receptors simultaneously
• Phase 3 trials: Ongoing; results from TRANSCEND-T2D-1 released March 2026
• Weight loss in trials: Up to 71.2 lbs average in Phase 3 obesity study (Dec 2025)
• FDA approval: Not yet approved — still in clinical trials
• Common misspellings: retrutide, retatutride, reditrutide, retattrutide, retartrutide, retatrudtide, retatruride

So What Actually Is Retatrutide?

Retatrutide is a once-weekly injectable peptide that works on three hormonal pathways at once — GLP-1, GIP, and glucagon. That triple-action approach is what sets it apart from drugs like Ozempic (semaglutide) or Mounjaro (tirzepatide), which hit one or two receptors respectively.

The results from clinical trials have been striking. In a Phase 2 trial, participants lost up to 17.5% of their body weight over 24 weeks. Phase 3 data published in late 2025 showed average losses of over 70 lbs in people with obesity. For context, that's well above what earlier GLP-1 drugs deliver.

Beyond weight loss, retatrutide is being studied for type 2 diabetes, osteoarthritis pain, and metabolic health broadly. The March 2026 TRANSCEND-T2D-1 results confirmed significant A1C reductions alongside weight loss in people with type 2 diabetes — a strong signal heading toward eventual FDA approval.

Why So Many Misspellings?

Honestly? The name is a mouthful. Retatrutide has a rhythm that trips people up — the "reta-tru-tide" syllable breakdown isn't obvious on first read. Common variations we see:

• retrutide — drops the first "ata," one of the most searched variants
• retatutride — swaps the "u" and "r" in the middle
• reditrutide — replaces "reta" with "redi"
• retattrutide — doubles the "t"
• retartrutide — adds an extra "r" before "tru"
• retatrudtide — sneaks a "d" into the back half
• retatruride — drops the final "t" before "-ide"

All roads lead to the same compound. Whatever spelling got you here, you're now looking at the right information.

Everything You Need to Know About Retatrutide

Use the links below to go deeper on any specific topic. These are the most complete resources we have on retatrutide:

Ready to Learn More?

If you want to explore retatrutide peptide options available right now, Ascension Peptides is one of our trusted partners offering high-quality sourcing with transparent lab testing.

Explore Retatrutide at Ascension Peptides →

Frequently Asked Questions

Q: Is retatrutide the same as retrutide?
A: Yes — "retrutide" is simply a misspelling of retatrutide. They refer to the same drug developed by Eli Lilly. You'll sometimes also see it written as retatutride, reditrutide, or retattrutide, all meaning the same thing.

Q: Has retatrutide been FDA approved?
A: Not yet as of early 2026. Retatrutide is still in Phase 3 clinical trials. The most recent data (TRANSCEND-T2D-1, March 2026) is very promising, but FDA approval is expected to come after trials are fully complete and submitted.

Q: How does retatrutide compare to semaglutide (Ozempic/Wegovy)?
A: Retatrutide targets three receptors (GLP-1, GIP, glucagon) vs. semaglutide's single receptor (GLP-1). Early data suggests retatrutide produces significantly more weight loss. See our retatrutide vs semaglutide.

Q: What kind of weight loss results have people seen?
A: Phase 3 data showed an average loss of up to 71.2 lbs over roughly a year in people with obesity. Phase 2 data showed up to 17.5% body weight reduction at 24 weeks — both are among the highest figures seen for any weight loss drug in trials.

Q: When will retatrutide be available to the public?
A: There's no confirmed FDA approval date yet. Based on current trial timelines, many analysts expect a submission in 2026 with potential approval in 2027 or later. Check our dedicated page for the latest: When will retatrutide be available?

Disclaimer

The information on this page is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and has not been approved by the FDA. Always consult a qualified healthcare provider before starting any new medication, supplement, or peptide protocol. Middlewaynutrition.com does not endorse self-administration of any unapproved substance.